Raffi Asadorian - Talphera Chief Officer
| TLPH Stock | 0.64 0.02 3.23% |
Executive
Raffi Asadorian is Chief Officer of Talphera
| Age | 55 |
| Address | 1850 Gateway Drive, San Mateo, CA, United States, 94404 |
| Phone | 650 216 3500 |
| Web | https://talphera.com |
Talphera Management Efficiency
The company has return on total asset (ROA) of (0.4726) % which means that it has lost $0.4726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.184) %, meaning that it created substantial loss on money invested by shareholders. Talphera's management efficiency ratios could be used to measure how well Talphera manages its routine affairs as well as how well it operates its assets and liabilities. The Talphera's current Return On Tangible Assets is estimated to increase to -1.51. The current Return On Capital Employed is estimated to decrease to -1.12. As of now, Talphera's Non Current Assets Total are decreasing as compared to previous years. The Talphera's current Other Current Assets is estimated to increase to about 3.7 M, while Total Assets are projected to decrease to under 19.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Shields | Teva Pharma Industries | 50 | |
| David Boyer | Neurocrine Biosciences | 45 | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| Christina Siniscalchi | Alvotech | N/A | |
| Jessica Perl | Emergent Biosolutions | N/A | |
| Jenny Steingrimsdottir | Alvotech | N/A | |
| Claire Dickson | Haleon plc | N/A | |
| Sonya Ghobrial | Haleon plc | 50 | |
| Ingrid Delaet | Neurocrine Biosciences | 58 | |
| Paul Williams | Emergent Biosolutions | 57 | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Bjorn Timelin | Haleon plc | N/A | |
| Matthew Abernethy | Neurocrine Biosciences | 44 | |
| Dov Bergwerk | Teva Pharma Industries | N/A | |
| Franck Riot | Haleon plc | 56 | |
| Ed Petter | Haleon plc | N/A | |
| Line Decker | Haleon plc | 50 | |
| Darin Esq | Neurocrine Biosciences | 58 | |
| Michelle Pepin | Emergent Biosolutions | N/A | |
| Kelly Warfield | Emergent Biosolutions | N/A | |
Management Performance
| Return On Equity | -1.18 | ||||
| Return On Asset | -0.47 |
Talphera Leadership Team
Elected by the shareholders, the Talphera's board of directors comprises two types of representatives: Talphera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Talphera. The board's role is to monitor Talphera's management team and ensure that shareholders' interests are well served. Talphera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Talphera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Angotti, CEO Director | ||
| Anil Dasu, Chief Officer | ||
| Shakil MD, Chief Officer | ||
| Pamela MD, CoFounder Officer | ||
| Raffi Asadorian, Chief Officer |
Talphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Talphera a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.18 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (40.45) % | ||||
| Current Valuation | 4.99 M | ||||
| Shares Outstanding | 16.99 M | ||||
| Shares Owned By Insiders | 1.16 % | ||||
| Shares Owned By Institutions | 30.91 % | ||||
| Number Of Shares Shorted | 41.94 K | ||||
| Price To Book | 1.20 X | ||||
| Price To Sales | 38.43 X |
Currently Active Assets on Macroaxis
When determining whether Talphera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Talphera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Talphera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Talphera Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Talphera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Talphera Stock please use our How to Invest in Talphera guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Talphera. If investors know Talphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Talphera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Revenue Per Share 0.018 | Return On Assets (0.47) | Return On Equity (1.18) |
The market value of Talphera is measured differently than its book value, which is the value of Talphera that is recorded on the company's balance sheet. Investors also form their own opinion of Talphera's value that differs from its market value or its book value, called intrinsic value, which is Talphera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Talphera's market value can be influenced by many factors that don't directly affect Talphera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Talphera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Talphera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Talphera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.